Author:
Borgohain Pritom,Shakya Anshul,Ghosh Surajit Kumar,Gogoi Neelutpal,Patgiri Saurav Jyoti,Bhowmick Ipsita Pal,Bhattacharyya Dibya Ranjan,Singh Udaya Pratap,Bhat Hans Raj
Funder
All India Council for Technical Education
Reference28 articles.
1. Design and development of novel N-(4-aminobenzoyl)- l-glutamic acid conjugated 1,3,5-triazine derivatives as Pf-DHFR inhibitor: an in-silico and in-vitro study;Adhikari;J. Biochem. Mol. Toxicol.,2023
2. Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: a systematic review of clinical studies from two malaria endemic regions - India and sub-Saharan Africa;Arya;Int. J. Parasitol. Drugs Drug Resist.,2021
3. Recent progress in the development of new antimalarial drugs with novel targets;Belete;Drug Des. Dev. Ther.,2020
4. Antimalarial activity and docking studies of novel bi-functional hybrids derived from 4-aminoquinoline and 1,3,5-triazine against wild and mutant malaria parasites as pf-DHFR inhibitor;Bhat;RSC Adv.,2013
5. Synthesis, characterization and antimalarialactivity of hybrid4-aminoquinoline-1,3,5-triazinederivatives;Bhat;Arab. J. Chem.,2016